IRIS
CAMELI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 13.929
NA - Nord America 13.502
AS - Asia 7.803
SA - Sud America 1.414
AF - Africa 507
OC - Oceania 40
Continente sconosciuto - Info sul continente non disponibili 9
AN - Antartide 1
Totale 37.205
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.205
IT - Italia 3.354
RU - Federazione Russa 3.295
SG - Singapore 2.592
CN - Cina 1.819
GB - Regno Unito 1.814
IE - Irlanda 1.658
BR - Brasile 1.169
VN - Vietnam 1.047
DE - Germania 847
HK - Hong Kong 805
SE - Svezia 740
FR - Francia 678
FI - Finlandia 510
IN - India 377
KR - Corea 306
ZA - Sudafrica 272
UA - Ucraina 202
NL - Olanda 178
ES - Italia 161
CA - Canada 157
BD - Bangladesh 119
JP - Giappone 112
IQ - Iraq 103
PL - Polonia 98
MX - Messico 93
CZ - Repubblica Ceca 78
TR - Turchia 70
CI - Costa d'Avorio 62
AR - Argentina 60
PK - Pakistan 59
AT - Austria 58
EC - Ecuador 48
NG - Nigeria 44
ID - Indonesia 43
IR - Iran 41
SA - Arabia Saudita 39
CH - Svizzera 36
VE - Venezuela 36
KE - Kenya 35
BE - Belgio 34
PH - Filippine 31
AU - Australia 30
MA - Marocco 29
UZ - Uzbekistan 29
LT - Lituania 26
AE - Emirati Arabi Uniti 25
CO - Colombia 25
CL - Cile 22
PY - Paraguay 19
EG - Egitto 18
JO - Giordania 18
MY - Malesia 18
PE - Perù 18
AZ - Azerbaigian 16
DK - Danimarca 16
HU - Ungheria 15
PT - Portogallo 15
BG - Bulgaria 14
IL - Israele 14
RO - Romania 14
TN - Tunisia 14
KZ - Kazakistan 13
AL - Albania 12
DZ - Algeria 12
JM - Giamaica 11
LB - Libano 11
NP - Nepal 11
PA - Panama 10
BO - Bolivia 9
GR - Grecia 9
KG - Kirghizistan 9
GE - Georgia 8
MK - Macedonia 8
NZ - Nuova Zelanda 8
OM - Oman 8
BY - Bielorussia 7
CY - Cipro 7
EE - Estonia 7
LV - Lettonia 7
PS - Palestinian Territory 7
SN - Senegal 7
EU - Europa 6
LA - Repubblica Popolare Democratica del Laos 6
LK - Sri Lanka 6
UY - Uruguay 6
CR - Costa Rica 5
DO - Repubblica Dominicana 5
HR - Croazia 5
NO - Norvegia 5
QA - Qatar 5
RS - Serbia 5
SK - Slovacchia (Repubblica Slovacca) 5
TH - Thailandia 5
AM - Armenia 4
KW - Kuwait 4
LU - Lussemburgo 4
TW - Taiwan 4
BB - Barbados 3
BH - Bahrain 3
Totale 37.147
Salva come PNG Salva come JPEG
Città #
Dallas 2.891
Dublin 1.627
Singapore 1.562
Southend 1.442
Ashburn 1.050
Moscow 991
Santa Clara 889
San Jose 758
Hong Kong 749
Fairfield 730
Chandler 716
Siena 494
Beijing 476
Hefei 455
Milan 383
Council Bluffs 370
Los Angeles 370
Munich 368
Helsinki 340
Woodbridge 321
Ho Chi Minh City 318
Lastra a Signa 314
Wilmington 306
Houston 303
Seoul 280
Seattle 269
New York 267
Florence 251
Johannesburg 243
Hanoi 238
Princeton 230
Cambridge 228
Lauterbourg 222
The Dalles 170
Rome 158
Ann Arbor 146
São Paulo 117
Jacksonville 108
Shanghai 97
Chicago 96
Orem 90
Redondo Beach 85
Tokyo 84
Bengaluru 83
Warsaw 82
Buffalo 77
Frankfurt am Main 77
San Mateo 76
Turku 76
Dong Ket 75
Lappeenranta 73
Fremont 70
London 70
Málaga 68
San Diego 68
Nuremberg 63
Abidjan 62
Chennai 61
Boardman 60
Düsseldorf 59
Da Nang 54
Portsmouth 52
Dearborn 51
Montreal 51
Stockholm 46
Brno 44
Rio de Janeiro 44
Brooklyn 43
Phoenix 43
Toronto 43
Atlanta 42
Haiphong 39
Manchester 39
Baghdad 36
Denver 35
Washington 35
Amsterdam 34
Poplar 34
Abuja 33
Naples 32
Boston 31
Vienna 31
Guangzhou 30
Brescia 29
Dhaka 28
Paris 27
Gavirate 26
San Francisco 26
Tashkent 26
Brasília 25
Mexico City 25
Mumbai 24
Olomouc 24
Padova 24
Salt Lake City 24
Zurich 24
Hyderabad 23
Lahore 23
Piscataway 23
Newark 22
Totale 24.147
Salva come PNG Salva come JPEG
Nome #
A first update on mapping the human genetic architecture of COVID-19 575
ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population 574
A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death 506
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 499
Genetic mechanisms of critical illness in COVID-19 409
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 387
An explainable model of host genetic interactions linked to COVID-19 severity 365
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis 349
Alveolar concentration of nitric oxide as a prognostic biomarker in idiopathic pulmonary fibrosis 342
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity 337
Pathogen-sugar interactions revealed by universal saturation transfer analysis 323
null 320
Peripheral biomarkers' panel for severe COVID-19 patients 316
Employing a systematic approach to biobanking and analyzing clinical and genetic data for advancing COVID-19 research 311
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 292
Long Covid: analisi di casistica in follow-up a seguito di successive ondate epidemiche 290
Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6 287
Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males 283
Antithrombin III as predictive indicator of survival in IPF patients treated with Nintedanib: a preliminary study 279
Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease 278
Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19 273
SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues 272
Exhaled nitric oxide in interstitial lung diseases 271
The effect of cigarette smoking on bronchoalveolar lavage protein profiles from patients with different interstitial lung diseases 271
ACUTE HF score, a multiparametric prognostic tool for acute heart failure: A real-life study 267
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib 261
Adiponectin and leptin levels in idiopathic pulmonary fibrosis: A new method for BAL and serum assessment 253
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 253
Adaptive immune system in pulmonary sarcoidosis - comparison of peripheral and alveolar biomarkers 250
The impact of antifibrotic therapy in the management of idiopathic pulmonary fibrosis and progressive fibrosing interstitial lung diseases: a real-world comparative study of efficacy between pirfenidone and nintedanib 247
Serial KL-6 measurements in COVID-19 patients 246
Prognostic bioindicators in severe COVID-19 patients 244
A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting 243
Omalizumab treatment in Samter's triad: case series and review of the literature 242
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes 242
Pleuroparenchymal fibroelastosis (PPFE) associated with giant cell arteritis: A coincidence or a novel phenotype? 241
Serum amyloid A in patients with idiopathic pulmonary fibrosis 236
A real-life experience with ImmunoCAP ISAC: the advantages of a new diagnostic method 235
Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab 235
Severe COVID-19 in hospitalized carriers of single CFTR pathogenic variants 235
Incremental value of pocket-sized imaging device for bedside diagnosis of unilateral pleural effusions and ultrasound-guided thoracentesis 234
Alveolar nitric oxide is related to periostin levels in idiopathic pulmonary fibrosis 233
AB0611 Neutrophil extracellular traps and interstitial lung disease in ANCA-associated vasculitis: a scoping review 232
Alveolar nitric oxide as a biomarker of COVID-19 lung sequelae: A pivotal study 231
Comparison of Right Versus Left Ventricular Strain Analysis as a Predictor of Outcome in Patients With Systolic Heart Failure Referred for Heart Transplantation 225
COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs 225
BAL biomarkers’ panel for differential diagnosis of interstitial lung diseases 224
BAL and serum multiplex lipid profiling in idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis 222
Serum KL-6 concentrations as a novel biomarker of severe COVID-19 219
NK and NKT-like cells in granulomatous and fibrotic lung diseases 216
Bronchoalveolar lavage and serum KL-6 concentrations in chronic hypersensitivity pneumonitis: correlations with radiological and immunological features 216
BAL Proteomic Signature of Lung Adenocarcinoma in IPF Patients and Its Transposition in Serum Samples for Less Invasive Diagnostic Procedures 214
Immune-Checkpoint Expression on CD4, CD8 and NK Cells in Blood, Bronchoalveolar Lavage and Lymph Nodes of Sarcoidosis 213
Ultra-rare RTEL1 gene variants associate with acute severity of COVID-19 and evolution to pulmonary fibrosis as a specific long COVID disorder 213
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena 211
A multicenter approach to evaluate omalizumab effectiveness in Samter’s triad 211
Krebs von den Lungen-6 as Disease Severity Marker for COVID-19 Patients: Analytical Verification and Quality Assessment of the Tosoh AIA-360 Compared to Lumipulse G600II 211
Cor pulmonale: the role of traditional and advanced echocardiography in the acute and chronic settings 207
Regulatory T Cells in Severe Persistent Asthma in the Era of Monoclonal Antibodies Target Therapies 204
WES profiling of COVID-19 204
Altered serum concentrations of IL-8, IL-32 and IL-10 in patients with lung impairment 6 months after COVID-19 203
Idiopathic Pulmonary Fibrosis Serum proteomic analysis before and after nintedanib therapy 203
Serum amyloid A: A potential biomarker of lung disorders 201
Serum concentrations of Krebs von den Lungen-6 in different COVID-19 phenotypes 200
Portable Pocket-Sized Ultrasound Scanner for the Evaluation of Lung Involvement in Coronavirus Disease 2019 Patients 199
Whole-genome sequencing reveals host factors underlying critical COVID-19 198
Efficacy of baricitinib in treating rheumatoid arthritis: Modulatory effects on fibrotic and inflammatory biomarkers in a real-life setting 196
Systematic review and metanalysis of oncomarkers in ipf patients and serial changes of oncomarkers in a prospective italian real-life case series 195
Collagen Type IV Alpha 5 Chain in Bronchiolitis Obliterans Syndrome After Lung Transplant: The First Evidence 192
Traditional and Novel Imaging of Right Ventricular Function in Patients with Heart Failure and Reduced Ejection Fraction 192
Clinical and molecular characterization of COVID-19 hospitalized patients 192
Right cardiac involvement in lung diseases: a multimodality approach from diagnosis to prognostication 191
Basic and advanced echocardiography in advanced heart failure: an overview 189
Protective role of a TMPRSS2 variant on severe COVID-19 outcome in young males and elderly women 189
Effects of rituximab therapy on B cell differentiation and depletion 188
The Role of Urinary Calcium and Chitotriosidase in a Cohort of Chronic Sarcoidosis Patients 187
Peripheral and alveolar biomarkers of fibrotic hypersensitivity pneumonitis 187
Serum Proteomic Profile of Asthmatic Patients after Six Months of Benralizumab and Mepolizumab Treatment 187
Severe asthma and long-term Benralizumab effectiveness in real-life 185
Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab 180
Krebs von den Lungen-6 as biomarker for disease severity assessment in interstitial lung disease: a comprehensive review 176
Left atrial strain as a pre-operative prognostic marker for patients with severe mitral regurgitation 176
Prognostic role of KL-6 in lymphangioleiomyomatosis patients 176
Peripheral lymphocyte subset monitoring in COVID-19 Italian patients 174
Metabolic Dysregulation in Idiopathic Pulmonary Fibrosis 174
Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study 173
Differential redox proteomic profiles of serum from severe asthma patients after one month of Benralizumab and Mepolizumab treatment 172
The Effects of Interstitial Lung Diseases on Alveolar Extracellular Vesicles Profile: A Multicenter Study 171
Serum CD59: a novel biomarker of idiopathic pulmonary fibrosis? 171
CD103 Expression on Regulatory and Follicular T Cells in Lymph Nodes, Bronchoalveolar Lavage Fluid and Peripheral Blood of Sarcoidosis Patients 169
Proteomic characterization of idiopathic pulmonary fibrosis patients: stable versus acute exacerbation 169
Common molecular pathways targeted by nintedanib in cancer and IPF: a bioinformatic study 169
Timing of Osteoporotic Vertebral Fractures in Lung and Heart Transplantation: A Longitudinal Study 167
Immunologic responses to antifibrotic treatment in IPF patients 165
Utility of serological biomarker' panels for diagnostic accuracy of interstitial lung diseases 163
Bone fragility and sarcoidosis: An underestimated relationship 162
Bronchoalveolar-Lavage-Derived Fibroblast Cell Line (B-LSDM7) as a new protocol for investigating the mechanisms of idiopathic pulmonary fibrosis 160
Exploring the interaction between fractional exhaled nitric oxide and biologic treatment in severe asthma: a systematic review 159
Cytological analysis of bronchoalveolar lavage fluid in asbestos-exposed workers: BALF features in asbestos exposed workers 158
Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy 157
Totale 23.919
Salva come PNG Salva come JPEG
Categoria #
all - tutte 126.038
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 126.038
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021641 0 0 0 0 0 0 0 0 0 174 239 228
2021/20222.553 187 281 225 182 124 114 110 118 114 321 269 508
2022/20233.028 200 342 390 305 186 521 261 265 210 123 127 98
2023/20243.392 132 93 328 173 170 737 956 193 56 119 127 308
2024/20257.932 607 312 846 453 960 485 452 458 644 394 729 1.592
2025/202617.057 1.279 2.445 2.254 2.176 3.399 642 2.287 600 739 1.236 0 0
Totale 38.203